In Vivo Targeting of Dendritic Cells with Artificial Adjuvant Vector Cells (aAVC) as a Novel Cancer Immunotherapy

An ideal cancer vaccine would inhibit tumor cells by inducing both innate and adaptive immunity, allowing for specific and long-term cancer immunosurveillance.